Healing Opioid Misuse and Pain Through Engagement (HOPE) Trial

Chronic Pain Clinical Trial

— HOPE  

Official title:

Integrative Treatment for Achieving Holistic Recovery From Comorbid Chronic Pain and Opioid Use Disorder

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05571917
• Other study ID #: 2206006784
• Secondary ID: RM1DA055301
• Status: Recruiting
• Phase: N/A
• Start date: May 5, 2023
• Est. completion date: December 31, 2026

Study information

• Verified date: June 2024
• Source: University of New Mexico
• Contact: Katie Witkiewitz, PhD
• Phone: (505) 585-1686
• Email: katiew[@]unm.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a multisite randomized clinical trial of a treatment designed to reduce pain interference while simultaneously addressing relapse prevention among individuals who have co-occurring chronic pain and Opioid Use Disorder (OUD). This study will recruit approximately 160 individuals who are currently being treated in clinics specializing in the physician management of OUD. To increase generalizability of study findings and increase internal validity of the physician management component of treatment, all participants will be stabilized on buprenorphine for OUD as part of their usual clinical care. Individuals will be randomized to either: (1) enhanced usual care or (2) the integrated ACT + MBRP treatment. The investigators hypothesize that: (1) the combination of ACT + MBRP in buprenorphine-prescribed patients with chronic pain will be more efficacious across primary and secondary outcome measures in comparison to Enhanced Usual Care and (2) examination of treatment mechanism data will indicate treatment-related changes that are consistent with the theoretical models of ACT+MBRP.

Description:

Opioid prescription in the treatment of chronic pain is frequent and carries a consequent risk of poor treatment outcome, as well as higher morbidity and mortality in a clinically significant number of patients, particularly those who meet criteria for OUD. Despite the alarming increases in opioid misuse and OUD nationally, there are few treatment options available that target both pain-related interference and OUD in an integrated fashion among patients with chronic pain. To date, there are no evidence-based treatment options that aim to minimize pain interference while simultaneously addressing OUD among individuals with medication prescribed for OUD.

The present trial builds upon a pilot study that tested the feasibility of integrating two empirically-supported psychosocial interventions, ACT to reduce pain interference and MBRP to reduce opioid misuse. Following successful integration of the interventions, outcome analyses found that the integrated ACT + MBRP intervention reduced both pain interference and opioid misuse at a 6-month follow-up in comparison to physician management alone.

This study is a multisite randomized clinical trial that will recruit approximately 160 individuals who are currently being treated in clinics specializing in the physician management of OUD. To increase generalizability of study findings and increase internal validity of the physician management component of treatment, all participants will be stabilized on buprenorphine for OUD as part of their usual clinical care. Individuals will be randomized to either: (1) enhanced usual care or (2) the integrated ACT + MBRP treatment.

The primary outcome, pain interference, will be assessed at the end of the active treatment phase and at 6- and 12-month follow-ups. Secondary outcomes will include pain intensity, depression, and pain-related fear, and an exploratory outcome of self-report of substance use with urine testing for confirmation. Treatment mechanism variables, including chronic pain acceptance, engagement in values-based action, and opioid craving will be assessed weekly during the active phase of treatment.

Our overall hypotheses are that: (1) the combination of ACT + MBRP in buprenorphine-prescribed patients with chronic pain will be more efficacious across primary and secondary outcome measures in comparison to EUC and (2) examination of treatment mechanism data will indicate treatment-related changes that are consistent with the theoretical models of ACT+MBRP.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Stabilized on a dose of buprenorphine for a period of at least 1 month. Buprenorphine stabilization will be defined as a consistent dose for at least 30 consecutive days.

2. Willing to comply with all study procedures and be available for the duration of the study.

3. Aged 18 years or older.

4. Enrolled as a patient in one of the participating clinics.

5. Presence of chronic pain for > 6 months in duration.

Exclusion Criteria:

1. Current or past diagnosis of schizophrenia, delusional disorder, psychotic or dissociative disorders.

2. Unable to read English.

3. Have a substance use disorder requiring a higher level of care than outpatient treatment (e.g., severe alcohol use disorder requiring inpatient detoxification).

Related Conditions & MeSH terms

• Chronic Pain
• Opioid Use Disorder
• Opioid-Related Disorders

Intervention

Behavioral:
• Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP)
This intervention is an integrated psychosocial treatment of two established treatments for chronic pain and Opioid Use Disorder (OUD). This intervention focuses on reducing pain interference and preventing relapse to opioid misuse.
• Enhance Usual Care (EUC)
This intervention consists of psychoeducational materials about chronic pain treatment resources, signs and management of opioid overdose and overdose prevention. This intervention also consists of a brief, remote visit with a study therapist, lasting approximately 15 minutes.

Locations

Country	Name	City	State
United States	University of New Mexico	Albuquerque	New Mexico
United States	University of Michigan	Ann Arbor	Michigan

Sponsors (4)

Lead Sponsor	Collaborator
University of New Mexico	National Institute on Drug Abuse (NIDA), University of Michigan, Wake Forest University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Pain Interference	Pain interference between participants randomized to ACT+MBRP vs EUC assessed by Pain interference will be measured via Patient Reported Outcome Measurement Information System (PROMIS) Bank v1.0 Pain Interference: The National Institutes of Health (NIH) PROMIS toolkit measure for pain interference. Each item ranges from 0 (not at all) to 5 (very much interfered) and higher scores reflect more severe pain interference. This questionnaire asks about pain interference in the past 7 days (collected once at baseline, post-treatment, and months 6 and 12).	Change from baseline through 12-month follow-up period
Secondary	Change in Pain Intensity	Pain intensity between participants randomized to ACT+MBRP vs EUC will be measured via the PROMIS Short Form (SF) Pain Intensity 1a of the Helping to End Addiction Long-Term (HEAL) Initiative. Pain intensity will be assessed via a 0 (no pain) to 10 (maximum possible pain) scale for the previous week (collected once at baseline, post-treatment, and months 6 and 12). Higher scores reflect more severe pain intensity.	Change from baseline through 12-month follow-up period
Secondary	Change in Depression	Depression symptoms between participants randomized to ACT+MBRP vs EUC will be measured via the Patient Health Questionnaire 9 (PHQ-9). The PHQ-9 will be used to assess depression symptoms via 9 self-report items. Response options on the PHQ9 range from 1 (not at all) to 4 (nearly every day) for frequency of depression symptoms in the previous 2 weeks (collected once at baseline, post-treatment, and months 6 and 12). Higher scores indicate more severe depression symptoms.	Change from baseline through 12-month follow-up period
Secondary	Change in Pain-Related Anxiety	Pain-related anxiety between participants randomized to ACT+MBRP vs EUC will be measured via the Pain Anxiety Symptom Scale (PASS). Response options on the PASS range from 1 (never) to 5 (always) for frequency of pain-related anxiety in the previous 7 days (collected once at baseline, post-treatment, and months 6 and 12). Higher scores indicate more severe pain-related anxiety.	Change from baseline through 12-month follow-up period
Secondary	Change in Pain Acceptance	Pain acceptance between participants randomized to ACT+MBRP vs EUC will be measured via the Chronic Pain Acceptance Questionnaire (CPAQ). The CPAQ assesses how often a given statement is true for the participant; response options range from a 0 (never true) to 6 (always true) with some items reverse scored. Higher scores indicate better pain acceptance. The CPAQ will be administered once at baseline, weekly during the intervention period, monthly during the intervention period, post-treatment, and months 6 and 12.	Change from baseline through 12-week treatment period and 12-month follow-up period
Secondary	Change in Valued-Action	Valued-actions between participants randomized to ACT+MBRP vs EUC will be measured via the Values Tracker (VT) to assess how effective the participant was within the previous week in engaging in actions or activities that align with their personal values. The VT will be administered once at baseline, weekly during the intervention period, monthly during the intervention period, post-treatment, and months 6 and 12. Responses are measured via a slider ranging from 1 (not at all) to 10 (most effective). Higher scores reflect better valued-action engagement.	Change from baseline through 12-week treatment period and 12-month follow-up period
Secondary	Change in Craving	Opioid craving between participants randomized to ACT+MBRP vs EUC will be measured via a modified version of the Penn Alcohol Craving Scale (PACS) where opioid-related cravings are assessed instead of alcohol-related cravings. Responses range from 0 to 6 where 0 represents the absence of the specific craving symptom in the item, and 6 represents the maximum intensity or frequency of the craving symptom in the item. Higher scores on the PACS reflect more severe opioid craving. Craving symptoms are assessed for the previous week (once at baseline, weekly during the intervention period, monthly during the intervention period, post-treatment, and months 6 and 12).	Change from baseline through 12-week treatment period and 12-month follow-up period